ARVINAS INC. DL-,001

At the Cantor Fitzgerald conference, Arvinas said the strategic shift from commercialization to advancing its own PROTAC pipeline is largely complete. The company’s cash runway extends into the second half of 2028, enough capital to advance four clinical programs to key Phase I data. Near-term catalysts are data for ARV-393 (lymphomas), LRRK2-102 (neurodegeneration), ARV-027 (Kennedy disease) and ARV-6723 (immuno-oncology); KRAS‑G12D is partner-led only and the PSP program has been pushed regulatory-wise to 2027. The commercial therapy VEPPANNU is being marketed by Rigel; milestone payments and tiered royalties are expected to provide additional revenue. » Mere på de.investing.com

Arvinas emphasized that with the commercial launch of Vepdegestrant the company is involved with a marketed product for the first time and that liquidity is sufficient through the second half of 2028. Management expects data from four clinical programs within 15 months, including ARV-393 (BCL6) and ARV-102 (LRRK2), is pursuing selective partnerships and will keep key programs such as SBMA in-house. The company sees continued development of its platform but warns of the usual regulatory, safety and execution risks that will determine near-term success. » Mere på de.investing.com

Arvinas reported Q1 2026 revenue of $15.6 million (estimate $17.16 million, Q1 2025: $188.8 million), mainly due to the restructuring of the partnership with Pfizer. Earnings per share were -$0.90, beating the expected -$0.93. The company significantly cut R&D and general & administrative expenses, extended its cash runway into the second half of 2028, and points to FDA approval for VEPPANU as a key milestone. The stock rose 1.45% in premarket trading to $9.80. » Mere på de.investing.com